Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024

WASHINGTON, Feb. 25, 2024 /PRNewswire/ — Longbio Pharma (Suzhou) Co., Ltd. (referred to as “Longbio Pharma”), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare…